Ad­u­canum­ab has its ap­proval — now, let cit­i­zen-sci­en­tists come to­geth­er to see if it works

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

Ed­i­tor’s Note: Mad­hav Tham­biset­ty was an ad­vi­sor on the FDA’s Pe­riph­er­al and Cen­tral Ner­vous Sys­tem Drugs ad­vi­so­ry com­mit­tee that vot­ed over­whelm­ing­ly not to rec­om­mend Alzheimer’s drug ad­u­canum­ab’s ap­proval by the FDA. Tham­biset­ty’s views in this op-ed are not re­flec­tions of the po­si­tions of the FDA or the NIH’s Na­tion­al In­sti­tute on Ag­ing, where he is a sec­tion chief of the clin­i­cal and trans­la­tion­al neu­ro­science sec­tion in the lab­o­ra­to­ry of be­hav­ioral neu­ro­science.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER